These cases were compared to 50 IDH-mutant astrocytomas and 104 IDH-wild-type glioblastomas that remained wild-type for all MMR genes at recurrence to determine the longitudinal effect of developing these mutations, particularly in the context of temozolomide therapy. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).